U.S. Government funding of Lilly’s LY-CoV555 antibody against COVID-19

Lilly recently requested an emergency use authorization for LY-CoV555, an antibody treatment candidate against COVID-19. Like other COVID-19 candidates, the discovery of LY-CoV555 was heavily supported by the U.S. government. The government of Canada has also awarded millions to manufacture… Continue Reading

WTO TRIPS Council (October 2020): European Union dismisses concerns that IPRs are a barrier to COVID-19 medicines and technologies

On Friday, 16 October 2020, the European Union provided the following perspectives during a three hour debate on the proposed waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19 co-sponsored by Eswatini, Kenya,… Continue Reading

WTO TRIPS Council (October 2020): Hungary answers queries posed by South Africa regarding Hungarian compulsory licensing provisions

At the October 2020 session of the World Trade Organization’s (WTO) TRIPS Council, under agenda item 1, IP measures in the context of COVID-19, the European Union read out Hungary’s detailed responses to questions posed in July 2020 (at the… Continue Reading

WTO TRIPS Council (October 2020): South Africa issues clarion call urging support for TRIPS waiver proposal

On Friday, 16 October 2020, members of the World Trade Organization’s (WTO) TRIPS Council held a three hour debate on the proposal (IP/C/W/669) first tabled by India and South Africa for a waiver from certain provisions of the TRIPS Agreement… Continue Reading

KEI Sues HHS and the Army over Access to COVID-19 Contracts

On Friday October 16, 2020, KEI filed a lawsuit (under the Freedom of Information Act) against the Department of Health and Human Services (HHS) and the U.S. Army regarding requests for COVID-19 research and development and procurement contracts awarding hundreds… Continue Reading

20 October 2020 – Save the Date – Government Funding of COVID-19 Vaccines and Other Medical Technologies

Government Funding of COVID-19 Vaccines and Other Medical Technologies DATE: Tuesday, 20 October 2020 TIME: EDT 9:00 to 10:30/UTC: 13:00 to 14:30/CEST: 15:00 to 16:30 CONVENER: Knowledge Ecology International (KEI) REGISTRATION: Please contact thiru [at] keionline.org BACKGROUND: On Tuesday, 20… Continue Reading

Taxpayers are subsidizing 80 percent of Regeneron’s COVID-19 treatment’s R&D costs

Regeneron Pharmaceutical recently applied for Emergency Use Authorization of its investigational COVID-19 treatment, REGN-COV2, after Donald Trump said that it cured him of COVID-19, suggesting that Regeneron expects to cash in on the treatment. Taxpayers, however, are funding 80 percent… Continue Reading

KEI written statement at the WHO Executive Board special session: Update on implementation of resolution WHA73.1 (2020) on the COVID-19 response

Knowledge Ecology International (KEI) is an accredited non-state actor at the World Health Organization (WHO). This is our statement at the WHO Executive Board Special Session on the COVID-19 response. https://extranet.who.int/nonstateactorsstatements/print/book/export/html/3916?destination=node/3916 Knowledge Ecology International Meeting: EB Special session on the… Continue Reading

WTO TRIPS Council: India and South Africa submit draft decision text on a waiver from certain provisions of the TRIPS Agreement for the prevention, containment and treatment of COVID-19.

On Friday, 2 October 2020, the World Trade Organization (WTO) published a joint submission by India and South Africa on a draft decision text to the WTO TRIPS Council on a waiver from certain provisions of the TRIPS Agreement for… Continue Reading